β2受體激動劑能夠提高氣道平滑肌細胞內cAMP水平，通過松弛氣道平滑肌實現(xiàn)氣管舒張的作用，已成為目前主要的慢性阻塞性肺疾病（COPD）治療藥物。奧達特羅是由勃林格殷格翰公司研發(fā)的用于治療COPD及哮喘的新分子實體。根據(jù)臨床研究的報道，作為一種每日給藥一次的新一代長效β2受體激動劑（LABA），其療效可維持24 h，使用方便且能夠提高患者的依從性，在一系列臨床試驗中表現(xiàn)出了良好的應用前景。

β2-Adrenoceptor agonists could increase the level of cAMP in airway smooth muscle cells and be used for the treatment of chronic obstructive pulmonary disease (COPD) due to their bronchodilatory effect. Olodaterol is a new molecular entity developed by Boehringer Ingelheim for the treatment of COPD and asthma. Published data of clinical research show that olodaterol is a promising once-daily long-acting β2-adrenoceptor agonist (LABA) and the curative effect could last over 24 h. LABA offers an improved convenience and better compliance for the patient.